Mark H Einstein1, Ntokozo Ndlovu2, Jeannette Lee3, Elizabeth A Stier4, Jeffrey Kotzen5, Madhur Garg6, Kathleen Whitney7, Shelly Y Lensing8, Mariza Tunmer9, Webster Kadzatsa10, Joel Palefsky11, Susan E Krown12. 1. Department of Obstetrics, Gynecology, & Women's Health, Rutgers New Jersey Medical School, Newark, NJ, United States of America. Electronic address: mark.einstein@rutgers.edu. 2. College of Health Sciences, University of Zimbabwe Harare, Zimbabwe. 3. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America. Electronic address: JYLee@uams.edu. 4. Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA, United States of America. Electronic address: elstier@bu.edu. 5. Department of Radiation Oncology, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: Jeffrey.Kotzen@wits.ac.za. 6. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, United States of America. Electronic address: MGARG@montefiore.org. 7. Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, United States of America. Electronic address: kwhitney@montefiore.org. 8. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America. Electronic address: SYLensing@uams.edu. 9. Radiation Oncology Wits Donald Gordon Medical Centre, Johannesburg, South Africa. Electronic address: mariza.tunmer@wits.ac.za. 10. Department Radiotherapy and Oncology, College of Health Science University of Zimbabwe, Harare, Zimbabwe. 11. Department of Medicine, University of California, San Francisco, San Francisco, CA, United States of America. Electronic address: Joel.Palefsky@ucsf.edu. 12. AIDS Malignancy Consortium, New York, NY, United States of America. Electronic address: krowns@mskcc.org.
Abstract
PURPOSE: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). PATIENTS AND METHODS: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4-45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. RESULTS: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82%) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94%) returned for follow-up. One-year progression-free survival was 76.3% (95% CI, 59.4-86.9%), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93% of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. CONCLUSIONS: The majority of HIV-infected women with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfected women with comparable tolerability and high ART adherence while on treatment.
PURPOSE: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infectedwomen with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART). PATIENTS AND METHODS: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41.4-45 Gy external beam radiation therapy followed by high dose rate brachytherapy concomitant with up to six weekly doses of cisplatin 40 mg/m2 and were followed for 12 months. RESULTS: Sixty-four women were screened at two sites in sub-Saharan Africa, of whom 40 eligible participants were enrolled, for a screening ratio of 1.60. Of the 38 eligible participants who initiated study treatment, 31 (82%) completed treatment. By the 12-month follow-up visit, 7 women had died of disease and 29 of 31 (94%) returned for follow-up. One-year progression-free survival was 76.3% (95% CI, 59.4-86.9%), and did not significantly differ according to stage at entry (p = 0.581). Participant-reported adherence to ART was high; by 12 months, 93% of participants had an undetectable viral load. The most common grade 3 or 4 adverse event was decreased lymphocyte count that affected all treated participants. Non-hematologic serious adverse events were similar to those observed in women with LACC without HIV infection. CONCLUSIONS: The majority of HIV-infectedwomen with LACC can complete concomitant chemoradiotherapy with the same cisplatin dose used in HIV-uninfectedwomen with comparable tolerability and high ART adherence while on treatment.
Authors: Hannah M Simonds; Matthys H Botha; Alfred I Neugut; Frederick H Van Der Merwe; Judith S Jacobson Journal: Gynecol Oncol Date: 2018-09-05 Impact factor: 5.482
Authors: M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Scott Dryden-Peterson; Memory Bvochora-Nsingo; Gita Suneja; Jason A Efstathiou; Surbhi Grover; Sebathu Chiyapo; Doreen Ramogola-Masire; Malebogo Kebabonye-Pusoentsi; Rebecca Clayman; Abigail C Mapes; Neo Tapela; Aida Asmelash; Heluf Medhin; Akila N Viswanathan; Anthony H Russell; Lilie L Lin; Mukendi K A Kayembe; Mompati Mmalane; Thomas C Randall; Bruce Chabner; Shahin Lockman Journal: J Clin Oncol Date: 2016-11-01 Impact factor: 44.544
Authors: Jacqueline Spayne; Ida Ackerman; Michael Milosevic; Allan Seidenfeld; Alan Covens; Lawrence Paszat Journal: Eur J Public Health Date: 2007-05-04 Impact factor: 3.367
Authors: Allen C Bateman; Katundu Katundu; Mulindi H Mwanahamuntu; Sharon Kapambwe; Vikrant V Sahasrabuddhe; Michael L Hicks; Benjamin H Chi; Jeffrey S A Stringer; Groesbeck P Parham; Carla J Chibwesha Journal: BMC Cancer Date: 2015-07-24 Impact factor: 4.430
Authors: Petmore Zibako; Mbuzeleni Hlongwa; Nomsa Tsikai; Sarah Manyame; Themba G Ginindza Journal: Int J Environ Res Public Health Date: 2022-07-28 Impact factor: 4.614
Authors: Lilie L Lin; David S Lakomy; Elizabeth Y Chiao; Robert M Strother; Meg Wirth; Ethel Cesarman; Margaret Borok; Naftali Busakhala; Carla J Chibwesha; Lameck Chinula; Ntokozo Ndlovu; Jackson Orem; Warren Phipps; Vikash Sewram; Samantha L Vogt; Joseph A Sparano; Ronald T Mitsuyasu; Susan E Krown; Satish Gopal Journal: JCO Glob Oncol Date: 2020-07
Authors: David S Lakomy; Juliana Wu; Dorothy Lombe; Emmanouil Papasavvas; Susan Citonje Msadabwe; Yimin Geng; Luis J Montaner; Elizabeth Chiao; Lilie L Lin Journal: Cancer Med Date: 2021-06-12 Impact factor: 4.452